Lutetium-(177Lu)-oxodotreotide/yttrium-90-DOTATOC

Excerpt

In a study of 25 patients who received peptide receptor radionuclide therapy (PRRT) during a period of 1997−2014, a patient [age and sex not stated] was described, who developed kidney toxicity during PRRT therapy with yttrium-90-DOTATOC and lutetium-(177Lu)-oxodotreotide for neuroendocrine tumour [routes and dosages not stated]. The patient, who had neuroendocrine tumour, had been receiving yttrium-90-DOTATOC [90Y-DOTATOC] and lutetium-(177Lu)-oxodotreotide [177Lu-DOTATATE] in combination with external beam radiation therapy. Subsequently, the patient developed grade I kidney toxicity [duration of treatment to reaction onset and outcome not stated]. …